Based on these observations, PAI-1 may prove to be a potential therapeutic target for overcoming tolerance to osimertinib and improving the prognosis of patients with EGFR-mutated NSCLC. The gene discussed is SERPINE1; the disease is non-small cell lung carcinoma.